Article Text

Download PDFPDF

P48-A109 Obstacles and perspectives in tissue engineered endothelial keratoplasty
  1. Thuret Gilles1,2,
  2. He Zhiguo1,
  3. Poinard Sylvain1,2,
  4. Dorado Oliver1,2,
  5. Aouimeur Ines1,
  6. Sagnial Tomy1,
  7. Coulomb Louise1,
  8. Moussa Olfa Ben1,
  9. Thuret Jean-Yves3,
  10. Perrache Chantal1,
  11. Crouzet Emmanuel1,
  12. Mentek Marielle1,
  13. Mascarelli Frederic1,
  14. Ninotta Sandrine4,
  15. Acquart Sophie4,
  16. Moisan Anaïck4,
  17. Gain Philippe1,2
  1. 1Biology, Imaging and Enginneering for Ophthalmology, BiiO, University Jean Monnet, Saint-Etienne, France
  2. 2Ophthalmology dpt, University Hospital, Saint-Etienne, France
  3. 3Department of Integrative Biology and Molecular Genetics (SBIGeM), CEA, Saclay, France
  4. 4French Blood Center, Saint-Etienne and Grenoble, France


Endothelial bioengineering is the simplest form of corneal bioengineering insofar as it consists of producing a large quantity of corneal endothelial cells and packaging them in a form that can be transplanted to the patient. It seems to be the most realistic solution to replace endothelial grafts made from donor corneas and thus allow, by domino effect, to reserve them for other indications of keratoplasty. Kyoto ophthalmologists (S Kinoshita, N Koizumi and N Okumura) were the pioneers of injection therapy by demonstrating its feasibility and safety, with an efficacy at 5 years comparable to that of conventional endothelial grafts. These pioneers, split into two distinct entities, are currently industrializing this therapy by injecting cells in suspension, in the USA (Aurion biotech) and in Asia (Actualeyes). In addition to injections, tissue engineered endothelial keratoplasty (TEEK) is a complementary research approach. They consist in reproducing in vitro grafts of the DMEK or DSAEK type by seeding the cultured cells on acorneo-compatible’ support. Several have passed the preclinical stages and one is in clinical trial in Asia. Suspension cells and TEEK each have advantages and limitations that make them complementary in the management of corneal endothelial diseases.

We will analyze why there is not yet an alternative process for mass production of corneal endothelial cells or clinical grade TEEK, systematically detailing the various bottlenecks identified, from the source of cells and media, to regulatory and economic aspects.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.